These findings suggest that APC mutation status may influence treatment response to FOLFOX in younger CRC patients and highlight the potential utility of pathway-specific AI agents for evaluating molecular markers within therapeutic contexts. The gene discussed is APC; the disease is colorectal carcinoma.